

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085408 A1

(51) International Patent Classification⁷: **C07D 239/47**,
401/14, 405/14, 409/14, 413/14, 417/14, 403/14, A61K
31/513, 31/5377, A61P 25/28

(21) International Application Number:
PCT/JP2004/004320

(22) International Filing Date: 26 March 2004 (26.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003-126021 26 March 2003 (26.03.2003) JP
2003-126022 26 March 2003 (26.03.2003) JP

(71) Applicants (for all designated States except US): **MITSUBISHI PHARMA CORPORATION** [JP/JP]; 6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka, 5410046 (JP). **SANOFI-SYNTHELABO** [FR/FR]; 174 AVENUE DE FRANCE PARIS, F-75013 (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WATANABE, Kazutoshi** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **UEHARA, Fumiaki** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **HIKI, Shinsuke** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION,


TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **YOKOSHIMA, Satoshi** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **USUI, Yoshihiro** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **OKUYAMA, Masahiro** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **SHODA, Aya** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **ARITOMO, Kelichi** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **KOHARA, Toshiyuki** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP). **FUKUNAGA, Kenji** [JP/JP]; c/o MITSUBISHI PHARMA CORPORATION, TOKYO OFFICE, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 1038405 (JP).

(74) Agent: **SIKS & CO.**; 8th Floor, Kyobashi-Nisshoku Bldg., 8-7, Kyobashi 1-chome, Chuo-ku, Tokyo, 1040031 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES



(I)

(57) Abstract: A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for preventive and/or therapeutic treatment of diseases such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C₁-C₁₂ alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C₁-C₈ alkyl group, an optionally partially hydrogenated C₆-C₁₀ aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C₁-C₆ alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C₂-C₆ alkylene group.





KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.